Breaking News

SRI, Sanofi Enter Drug Discovery Collaboration

Will leverage SynFini, SRI’s artificial intelligence and automation platform to accelerate development of small-molecule drug targets.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SRI International entered a research collaboration with Sanofi that will leverage SRI’s SynFini platform, an artificial intelligence (AI)-guided, automated synthetic-chemistry system, to discover and develop lead candidates in multiple high-profile drug-discovery programs at Sanofi.   SRI’s SynFini platform combines AI and automation to accelerate small molecule drug discovery and development to bring new drugs to the clinic faster. The platform comprises three components (SynRoute, SynJet and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters